Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alza's OROS delivery system

Executive Summary

Firm announced on June 19 that its oral osmotic technology will be applied to Glaxo's Ventolin (albuterol) bronchodilator and to Pfizer's Minipress (prazosin) antihypertensive, under joint development agreements with the two pharmaceutical mfrs. Glaxo and Pfizer will make and market the controlled release formulations under a royalty-bearing license from Alza. Pfizer has a similar agreement for an OROS version of the calcium channel blocker Procardia (nifedipine).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel